Overview

Treatment of Primary CNS Lymphoma

Status:
Unknown status

Trial end date:
2020-06-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to evaluate the efficacy and safety of FVD regiment (fotemustine, teniposide and dexamethasone ) for patients with primary CNS lymphoma.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Mingzhi Zhang

Collaborator:

Zhengzhou University

Treatments:

Cytarabine
Fotemustine
Teniposide

Criteria

Inclusion Criteria:Age range 14-60 years old; ECOG performance status 0-2; Estimated
survival time > 3 months Histological confirmed PCNSL None of chemotherapy or radiotherapy
has been previously used None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl,
neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤
1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L,
serum plasminogen is normal (Inclusion Criteria of 1,3,6 groups ) At least one measurable
lesion None of other serious diseases, cardiopulmonary function is normal Pregnancy test of
women at reproductive age must be negative Patients could be followed up None of other
relative treatments including the traditional Chinese medicine, immunotherapy,biotherapy
except anti-bone metastasis therapy and other symptomatic treatments.

volunteers who signed informed consent. -

Exclusion Criteria:Disagreement on blood sample collection Patients allergic of any of drug
in this regimen or with metabolic disorder Pregnant or lactating women Serious medical
illness likely to interfere with participation Serious infection Primitive or secondary
tumors of central nervous system Chemotherapy or radiotherapy contraindication The evidence
of peripheral nervous disorder or dysphrenia patients participating in other clinical
trials patients taking other antitumor drugs patients estimated to be unsuitable by
investigato

-